 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 GLOBE NEWSWIRE -- Tricida, Inc. Nasdaq: TCDA, a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease CKD, announced today financial results for the fourth quarter and year ended December 31, 2020 and provided an update on key initiatives. 